But a number in the safety data spooked a few of us that were paying extra attention to the details: Dysesthesia occurred in 20.9% of participants on the 12 mg dose
Temperature: The Unflinching Tyrant of Peptide Stability We can't stress this enough: temperature is the single most dominant factor in the degradation equation
(Triple Agonist Explained) Retatrutide (also known as LY3437943) is a triple receptor agonist , meaning it interacts with: GLP-1 receptors (appetite & insulin signalling) GIP receptors (metabolic regulation) Glucagon receptors (energy expenditure pathways) Most older compounds target one or two pathways
Compounding versions of semaglutide are only allowed when there's an official shortage, because compounded semaglutide may use semaglutide salts, which are not the same as the approved semaglutide, and is not subject to the same rigorous safety and quality standards
Counting the days since you had your last poop? Oof
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2), The Lancet, 2025
